NALOXONE HYDROCHLORIDE

Post-LOE

naloxone hydrochloride

Fresenius Kabi

ANDAINJECTIONINJECTABLE

Approved

Apr 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

NALOXONE HYDROCHLORIDE (naloxone hydrochloride) by Fresenius Kabi is clinical pharmacology complete or partial reversal of opioid depression naloxone prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. Approved for depression. First approved in 2024.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Complete or Partial Reversal of Opioid Depression Naloxone prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. Also, Naloxone can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.…

Worked on NALOXONE HYDROCHLORIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

NALOXONE HYDROCHLORIDE

Mechanism of Action

Indications (1)